Trial Profile
A Phase I Trial of Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 09 May 2023 Status changed from active, no longer recruiting to completed.
- 19 Apr 2023 Results by deriving Tumor biopsies; angiogenic target of immune exclusion with checkpoint blockade in melanoma, presented at the 114th Annual Meeting of the American Association for Cancer Research
- 20 Dec 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.